- Demographics characteristics of patients included in this study.
| Demographics | n=41 | Rheumatology clinic | Pulmonary clinic | P-value |
|---|---|---|---|---|
| Female gender (%) | 32 (78) | 13 (93) | 19 (70) | 0.099 |
| Age at diagnosis (years) | 54.8 ± 13.4 | 46.9 ± 10.9 | 59±12.9 | <0.001 |
| Age at study inclusion (years) | 58.76 ± 12.7 | 52.9 ± 11.9 | 61.8 ± 12.2 | 0.003 |
| Disease duration (years) | 4.6 ± 2.3 | 6 ± 2.5 | 3.9 ± 1.8 | 0.003 |
| Time from symptom onset to diagnosis (years) | ||||
| Mean | 2.2 ± 2.4 | |||
| Range | 1-11 | |||
| Outcome measures | ||||
| Mean EULAR Sjogren’s Syndrome Disease Activity Index | 9.95 ± 7.73 | 6.43 ± 9.41 | 11.78±6.13 | 0.100 |
| Mean EULAR Sjogren’s Syndrome Patient Reported Outcome | 5.17 ± 2.4 | 5.095 ± 2.700 | 5.205±2.239 | 0.386 |
| Mean Patient Global Assessment | 5.2 ± 2.37 | 4.786 ± 2.723 | 5.423±2.176 | 0.864 |
| Mean Physician Global Assessment | 4.46 ± 2.06 | 3.786 ± 2.455 | 4.815±1.777 | 0.879 |
| Antibody profile; n (%) | ||||
| ANA | 32 (78.0) | 13 (93) | 19 (70) | 0.099 |
| Anti-SSA | 19 (46.3) | 12 (86) | 7 (26) | <0.001 |
| Anti-SSB | 12 (29.3) | 9 (64) | 3 (11) | <0.001 |
| Rheumatoid factor | 10 (24.4) | 11 (79) | 8 (30) | 0.168 |
| Presence of extra-glandular manifestations | 36 (87.8) | 9 (64) | 27 (100) | 0.001 |
EULAR: The European League Against Rheumatism, SSA: Sjogren’s syndrome A antibody,SSB: Sjogren’s syndrome B antibody,